- Trials with a EudraCT protocol (654)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
654 result(s) found for: Breast biopsy.
Displaying page 1 of 33.
EudraCT Number: 2007-001526-27 | Sponsor Protocol Number: STH14707 | Start Date*: 2007-06-19 | |||||||||||
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | |||||||||||||
Full Title: ANZAC: A Randomised Phase II Feasibility Study Investigating The Biological Effects of the Addition of Zoledronic Acid To Neoadjuvant Comnination Chemotherapy On Invasive Breast Cancer | |||||||||||||
Medical condition: Breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014823-22 | Sponsor Protocol Number: LISER-M | Start Date*: 2009-07-28 | |||||||||||
Sponsor Name:AZIENDA USL DI FORLI` | |||||||||||||
Full Title: Second biopsy of axillary sentinel node in the local recurrence of breast cancer after mastectomy and first negative sentinel node. Studio LiSeR - M | |||||||||||||
Medical condition: patients with first local recurrence of breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005863-32 | Sponsor Protocol Number: MAST1 | Start Date*: 2008-11-27 | |||||||||||
Sponsor Name:Department of Oncology | |||||||||||||
Full Title: A Phase II Study of Neo-Adjuvant Statin Therapy in Postmenopausal Primary Breast Cancer - a Window-of Opportunity Study | |||||||||||||
Medical condition: Postmenopausal women with primary invasive breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004194-16 | Sponsor Protocol Number: IRFMN-BRC-6591 | Start Date*: 2015-01-19 | |||||||||||
Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | |||||||||||||
Full Title: A multicenter, single-arm, phase II study to evaluate the activity of pre-operative zoledronate in triple negative breast cancer patients, according to p53 level | |||||||||||||
Medical condition: Newly diagnosed, untreated, operable triple negative breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005349-20 | Sponsor Protocol Number: 2/2013 | Start Date*: 2013-01-15 | |||||||||||
Sponsor Name:Kuopio University Hospital | |||||||||||||
Full Title: Diagnostic accuracy of contrast-enhanced ultrasound-guided axillary core biopsy in preoperative staging of the newly diagnosed invasive breast cancer - a prospective study. | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005114-33 | Sponsor Protocol Number: s57283 | Start Date*: 2015-03-10 | |||||||||||
Sponsor Name:UZ Leuven | |||||||||||||
Full Title: Effectiveness of Botulinum Toxin Infiltration for treatment of upper limb dysfunctions after treatment for breast cancer | |||||||||||||
Medical condition: The aim of this study is to examine the effect of Botolinum Toxine infiltration in the pectoral muscle, in combination with an individual physical therapy programme, on pain and upper limb dysfunct... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018862-22 | Sponsor Protocol Number: MammaMRI-PreBiopsy | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Kliniken Essen-Mitte | |||||||||||||
Full Title: Exploratory study to evaluate different MRI-contrast-agent-application-schemes using Gadovist to optimize contrast enhancement for longer lasting breast examination | |||||||||||||
Medical condition: Patients with recent diagnosis of breast cancer, histologically proven. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001587-19 | Sponsor Protocol Number: UHSM0315 | Start Date*: 2015-07-15 | |||||||||||||||||||||
Sponsor Name:Manchester University NHS Foundation Trust | |||||||||||||||||||||||
Full Title: A pilot prevention study of the effects of the anti-progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk | |||||||||||||||||||||||
Medical condition: We seek to investigate the breast cancer risk reducing properties of ulipristal acetate | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003220-52 | Sponsor Protocol Number: CC-486-BRSTM-001 | Start Date*: 2015-03-21 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 2, Randomized, Open-Label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Postmenopausal female subjects with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer, who have progressed on an aromatase inhibi... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-000520-14 | Sponsor Protocol Number: IEO S291/106 | Start Date*: 2006-10-26 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: A PHASE II STUDY OF GW572016 LAPATINIBTM ON CELL PROLIFERATION IN HER-2/neu ErbB2 POSITIVE BREAST CANCER BEFORE SURGERY. | |||||||||||||
Medical condition: Primary breast cancer T1-3 N0-1 M0 Histologically-confirmed HER 2 positive | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006025-27 | Sponsor Protocol Number: IEOS380/607 | Start Date*: 2008-11-10 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with bevacizumab and erlotinib (BEXE), plus trastuzumab in HER2/neu positive tumors (BEXET), in adv... | |||||||||||||
Medical condition: advanced or metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006430-10 | Sponsor Protocol Number: CTKI258A2202 | Start Date*: 2009-06-22 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multi-center, open label Phase II trial of TKI258 in FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer. | |||||||||||||
Medical condition: In female patients with FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) ES (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002077-21 | Sponsor Protocol Number: ICR-CTSU/2017/10065 | Start Date*: 2019-04-18 | |||||||||||
Sponsor Name:The Institute of Cancer Research | |||||||||||||
Full Title: PHOENIX Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemoth... | |||||||||||||
Medical condition: Triple Negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003932-32 | Sponsor Protocol Number: ESTEeM 112984 U106/7672 | Start Date*: 2006-12-14 | |||||||||||
Sponsor Name:The University of Leeds
[...]
1. The University of Leeds
2. The University of Sheffield |
|||||||||||||
Full Title: Endocrine +/- Surgical Therapy for Elderly women with Mammary cancer | |||||||||||||
Medical condition: Women 75 years or over with invasive, operable, moderate or strongly ER+ve, primary breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000764-42 | Sponsor Protocol Number: UC-0140/1606 | Start Date*: 2016-10-12 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration Afte... | |||||||||||||
Medical condition: Patients with ER+ and HER2- primary non-metastatic breast cancer who are eligible to neoadjuvant endocrine therapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001889-14 | Sponsor Protocol Number: Bubble2012 | Start Date*: 2012-10-15 | ||||||||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust | ||||||||||||||||||
Full Title: MicroBubble detection and Ultrasound guided Biopsy of axillary Lymph nodes in patients with Early breast cancer. | ||||||||||||||||||
Medical condition: Diagnosis of lymph node metastases in patients with newly diagnosed breast cancer. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-021220-10 | Sponsor Protocol Number: D2610C00003 | Start Date*: 2010-10-07 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised Double-blind Phase IIa Study (with Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination with Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Pa... | |||||||||||||
Medical condition: ER+ Breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) DE (Completed) HU (Completed) CZ (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004613-18 | Sponsor Protocol Number: MH-131 | Start Date*: 2007-06-04 | |||||||||||
Sponsor Name:BRACCO IMAGING | |||||||||||||
Full Title: Phase III, Multicenter, Double-blind, Randomized, Crossover Study to Compare MultiHancE with MagnevisT in Contrast-Enhanced MagnetiC Resonance Imaging MRI of the BreasT. - DETECT - | |||||||||||||
Medical condition: patiens with breast lesions which are highly suspicious or already known for malignancy which are requested for MRI | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) GB (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003194-28 | Sponsor Protocol Number: PULSION-001 | Start Date*: 2011-10-24 | |||||||||||
Sponsor Name:PULSION Medical Systems SE | |||||||||||||
Full Title: Determination of the sensitivity of ICG fluorescence technique for the detection of Sentinel Lymph Nodes in breast cancer – a monocenter, prospective open-label clinical trial | |||||||||||||
Medical condition: Breast cancer with indicated sentinel lymph node biopsy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003509-41 | Sponsor Protocol Number: GBG90 | Start Date*: 2016-08-01 | |||||||||||
Sponsor Name:GBG Forschungs GmbH | |||||||||||||
Full Title: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patien... | |||||||||||||
Medical condition: Patients with triple negative or HRpositive, early breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
